Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 1,656 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Growth Clear all
Completed No phase listed Observational Accepts healthy volunteers Results available

Translational Investigation of Growth and Everyday Routines in Kids

NCT02784509
View directory record Official record
Conditions
Childhood Obesity
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
10 Years to 16 Years
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 22, 2026, 2:19 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

NCT00790400
View directory record Official record
Conditions
Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM)
Interventions
Everolimus (RAD001), Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • Phoenix, Arizona • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 22, 2026, 2:19 PM EDT
Terminated Not applicable Interventional Results available

Effect of Moderate Caloric Restriction on Glomerular Growth After Kidney Transplantation

NCT03607500
View directory record Official record
Conditions
Kidney Transplant; Complications, Glomerular Disease, Weight Gain, Kidney Transplant
Interventions
caloric intake reduction
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 22, 2026, 2:19 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial

NCT04087941
View directory record Official record
Conditions
Painful Diabetic Neuropathy
Interventions
VM-202
Biological
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 22, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Preliminary Testing of New Treatment for Chronic Leg Wounds

NCT00000431
View directory record Official record
Conditions
Varicose Ulcer
Interventions
PDGF-B/Ad5
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 22, 2026, 2:19 PM EDT
Terminated Phase 2 Interventional Results available

Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury

NCT04051957
View directory record Official record
Conditions
Kidney Injury, Proteinuria, Hypertension
Interventions
Isosorbide Mononitrate, Placebo oral tablet
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 22, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

NCT01783444
View directory record Official record
Conditions
Breast Cancer
Interventions
Capecitabine, Exemestane, Everolimus
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Fort Myers, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 22, 2026, 2:19 PM EDT
Terminated No phase listed Observational

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

NCT00121875
View directory record Official record
Conditions
Turner Syndrome, Idiopathic Short Stature
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced Oct 22, 2026, 2:19 PM EDT
Completed Not applicable Interventional

Developing e-Health Systems to Improve Growth and Nutrition in CF

NCT03635762
View directory record Official record
Conditions
Cystic Fibrosis in Children
Interventions
Be In Charge
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
3 Years to 10 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Stanford, California • Aurora, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 22, 2026, 2:19 PM EDT
Terminated Phase 2 Interventional

Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults

NCT00527046
View directory record Official record
Conditions
Aging, Frail Older Adults
Interventions
CP-424,391
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 84 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
12
States / cities
Palo Alto, California • San Diego, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 22, 2026, 2:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy

NCT00711061
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Not listed
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 10, 2009 · Synced Oct 22, 2026, 2:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)

NCT02753595
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Eribulin mesylate, Biologic: PEGylated recombinant human hyaluronidase (PEGPH20), Biologic: PEGylated recombinant human hyaluronidase
Drug · Other
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
7
States / cities
Whittier, California • Atlanta, Georgia • Newnan, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 22, 2026, 2:19 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)

NCT00233519
View directory record Official record
Conditions
Myotonic Dystrophy
Interventions
SomatoKine/IPLEX
Drug
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2012 · Synced Oct 22, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma

NCT04205630
View directory record Official record
Conditions
Endometrial Cancer
Interventions
SYD985
Drug
Lead sponsor
Byondis B.V.
Industry
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 22, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation

NCT00457145
View directory record Official record
Conditions
Telangiectasia
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 2:19 PM EDT
Active, not recruiting No phase listed Observational

Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease

NCT00005902
View directory record Official record
Conditions
Hemangioblastoma, Hippel Lindau Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
8 Years to 75 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 22, 2026, 2:19 PM EDT
Terminated Phase 1 Interventional

Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)

NCT01748812
View directory record Official record
Conditions
Osteomalacia
Interventions
Osteomalacia
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 22, 2026, 2:19 PM EDT
Active, not recruiting Phase 1 Interventional

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer

NCT04042701
View directory record Official record
Conditions
Breast Cancer, Non-small Cell Lung Carcinoma
Interventions
Trastuzumab deruxtecan (DS-8201a), Pembrolizumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
San Francisco, California • New Haven, Connecticut • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 22, 2026, 2:19 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Research On Advanced Diagnostics and Management of All Pregnancies to Prevent Stillbirth (ROADMAPS)

NCT07745101
View directory record Official record
Conditions
Stillbirth
Interventions
Not listed
Lead sponsor
RTI International
Other
Eligibility
18 Years and older · Female only
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
5
States / cities
San Diego, California • New York, New York • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 22, 2026, 2:19 PM EDT
Completed Phase 1 Interventional

Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation

NCT00457067
View directory record Official record
Conditions
Telangiectasia
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 2:19 PM EDT
Recruiting Phase 1 Interventional

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

NCT07181681
View directory record Official record
Conditions
Solid Tumors, Advanced Solid Tumor
Interventions
BG-C0902
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 2:19 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer

NCT01565083
View directory record Official record
Conditions
Breast Cancer
Interventions
Pertuzumab, Trastuzumab, Vinorelbine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
17
States / cities
Tucson, Arizona • Stanford, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 22, 2026, 2:19 PM EDT
Completed Phase 2 Interventional

Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy

NCT01442090
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Everolimus, GDC-0980
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
8
States / cities
Fort Myers, Florida • St. Petersburg, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 22, 2026, 2:19 PM EDT
Recruiting Not applicable Interventional

A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

NCT06127979
View directory record Official record
Conditions
Breast Cancer
Interventions
blood draw
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 2:19 PM EDT